In the preceding three months, 16 analysts have released ratings for Moderna (NASDAQ:MRNA), presenting a wide array of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 3 | 8 | 3 | 0 |
| Last 30D | 0 | 0 | 0 | 1 | 0 |
| 1M Ago | 1 | 1 | 1 | 1 | 0 |
| 2M Ago | 1 | 1 | 2 | 0 | 0 |
| 3M Ago | 0 | 1 | 5 | 1 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $84.0, a high estimate of $139.00, and a low estimate of $40.00. This current average has decreased by 25.36% from the previous average price target of $112.54.
Decoding Analyst Ratings: A Detailed Look
The perception of Moderna by financial experts is...
Login or create a forever free account to read this news
Sign up/Log in
